Argon inhalation attenuates the liver and intestine via modulation of the Toll-like receptor 4 pathway after experimental neonatal sepsis

Technical Summary: Argon Inhalation Attenuates Liver and Intestine Injury via TLR4 Modulation in Neonatal Sepsis

Problem Statement
Neonatal sepsis remains a leading cause of mortality and morbidity, characterized by a systemic inflammatory response that frequently results in multi-organ dysfunction. The liver and intestine are particularly vulnerable due to their roles in metabolism, immunity, and barrier function. Sepsis-induced inflammation leads to intestinal barrier disruption, allowing bacterial translocation, and exacerbates liver injury. Current treatments rely on antibiotics and supportive care, but novel therapeutic avenues are needed. Given that neonates with sepsis are frequently mechanically ventilated, inhalation therapy presents a viable delivery route. While noble gases like argon have demonstrated protective effects in various pathological models via modulation of Toll-like receptor 4 (TLR4) signaling, their specific efficacy and mechanisms regarding liver and intestinal injury in the context of neonatal sepsis had not been extensively studied.

Methodology
The study utilized an experimental neonatal sepsis model in C57BL/6 mouse pups (Postnatal Day 9). Sepsis was induced via intraperitoneal injection of lipopolysaccharide (LPS) at 20 mg/kg. Immediately following induction, septic pups were exposed to an inhalation mixture of 70% argon and 30% oxygen in a sealed chamber for 6 hours. Control groups included non-septic mice and septic mice not exposed to argon.

The investigation employed a multi-faceted analytical approach:

• Histopathology: Liver, distal ileum, and colon tissues were analyzed via H&E staining and scored for inflammation, feathery degeneration, steatosis (liver), and mucosal damage (intestine).
• Immunofluorescence and Western Blotting: Tissues were assessed for macrophage infiltration (Iba1+), proinflammatory cytokine expression (IL-6, IL-1β), and tight junction proteins (Claudin-2 and Claudin-7).
• Molecular Analysis: RT-qPCR and Western blotting were used to quantify mRNA and protein levels of the TLR4 signaling pathway components, including TLR4, MyD88, phosphorylated IκBα, and NF-κB.
• In Vitro Modeling: Small intestinal organoids derived from neonatal mice were cultured and exposed to LPS with or without argon inhalation to assess growth (Ki67), proliferation, and epithelial integrity (E-cadherin).
• Safety Validation: Survival rates and neonatal motor function (hindlimb foot angle, surface righting, and hindlimb suspension tests) were evaluated in healthy pups exposed to argon to rule out toxicity.

Key Results

• Organ Protection: Argon inhalation significantly attenuated LPS-induced liver injury, reducing inflammation, feathery degeneration, and steatosis. Similarly, it prevented intestinal damage in the distal ileum and colon, preserving villus structure and preventing necrosis.
• Inflammation Modulation: Treatment reduced the infiltration of macrophages (Iba1+ cells) in both liver and intestinal tissues. Consequently, mRNA and protein levels of proinflammatory cytokines IL-6 and IL-1β were reduced to baseline levels in argon-treated septic mice.
• Barrier Integrity: Argon administration preserved intestinal barrier function. It decreased the expression of the permeability-associated tight junction protein Claudin-2 (which is upregulated by IL-6) and maintained the expression of the stability-associated Claudin-7.
• Mechanism of Action: The protective effects were mediated through the modulation of the TLR4 signaling pathway. Argon inhalation prevented the LPS-induced upregulation of TLR4 and its downstream adaptor MyD88. Furthermore, it inhibited the phosphorylation of IκBα and the subsequent nuclear translocation of NF-κB, thereby suppressing the transcription of proinflammatory genes.
• Organoid Validation: In LPS-injured intestinal organoids, argon exposure prevented growth arrest, maintained Ki67 expression (proliferation), and preserved E-cadherin expression (epithelial architecture).
• Safety Profile: Argon inhalation in healthy neonatal pups resulted in 100% survival and no observable deficits in cognitive or motor function compared to controls.

Significance and Claims
The authors claim this is the first study to investigate the therapeutic effect of argon inhalation specifically on liver and intestinal injury during experimental neonatal sepsis. The study demonstrates that argon inhalation is a viable therapeutic option that:

1. Attenuates Multi-Organ Injury: It effectively mitigates inflammation and structural damage in the liver and intestine.
2. Preserves Barrier Integrity: It maintains intestinal barrier function by regulating tight junction proteins, potentially preventing bacterial translocation.
3. Elucidates Mechanism: It confirms that these benefits are mechanistically linked to the suppression of the TLR4/MyD88/NF-κB signaling cascade.
4. Ensures Safety: It establishes a safety profile for argon inhalation in neonatal mice, showing no adverse effects on survival or neurodevelopmental motor functions.

The paper concludes that because neonates with sepsis are often mechanically ventilated, the transition to argon inhalation as a clinical therapy is feasible. The study positions argon as a promising strategy to improve outcomes in neonatal sepsis by targeting the inflammatory drivers of multi-organ dysfunction.